A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates. Hahn AW, Manyam GC, Chapin BF, Zhang M, et al. BJU Int 2024 Jun 4. doi: 10.1111/bju.16414.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Hahn AW, Manyam GC, Chapin BF, Zhang M, et al. A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates. BJU Int 2024 Jun 4. doi: 10.1111/bju.16414.
PMID: 38837608